Unmet needs in urothelial cancer management represent an important challenge in our effort to improve long-term overall and disease-free survival rates with no significant compromise in quality of life. Radical cystectomy with pelvic lymph node dissection is the standard for the management of muscle-invasive, non-metastatic cancers. In spite of a 90% local disease control, up to 50% of patients ultimately die of distant metastasis. Bladder preservation using chemo-radiation is an acceptable alternative, but optimal patient selection remains elusive. Recent research is focused on the employment of tailored-made strategies in urothelial cancer exploiting the potential of theranostics in patient selection for specific therapies. Herein, we review the current knowledge on molecular theranostics in urothelial cancer and we suggest that this is the time to move toward imaging theranostics, if tailored-made disease management and patient stratification is envisaged.
Katsila, T., Liontos, M., Patrinos, G. P., Bamias, A., & Kardamakis, D. (2018, February 1). The New Age of -omics in Urothelial Cancer – Re-wording Its Diagnosis and Treatment. EBioMedicine. Elsevier B.V. https://doi.org/10.1016/j.ebiom.2018.01.044